Abbvie (ABBV) Weakness Related to Hep-C Data from Gilead (GILD), BMO Capital Says
Tweet Send to a Friend
BMO Capital analyst Alex Arfaei weighed in on Abbvie (NYSE: ABBV) following Q1 results. The analyst said Street Hep-C ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
